Could a liver drug shrink polyps in a rare gut condition?

NCT ID NCT05223036

First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 29 times

Summary

This study tests whether a daily pill called obeticholic acid (OCA) can safely reduce the number of polyps in the small bowel and colon of people with familial adenomatous polyposis (FAP), a rare inherited condition that greatly raises the risk of intestinal cancer. About 80 adults with FAP will receive either OCA or a placebo for a set period, and doctors will measure changes in polyp burden and side effects. OCA is already approved for a liver disease, but its effect on polyps in FAP is unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • University of Kansas Cancer Center

    Kansas City, Kansas, 66160, United States

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • University of Puerto Rico

    San Juan, 00936, Puerto Rico

Conditions

Explore the condition pages connected to this study.